Lead-212 Radio-DARPin therapy (Molecular Partners/Orano Med)

N/A

Report date: 2025/11/24 17:31:47

Base Information

Drug NameLead-212 Radio-DARPin therapy (Molecular Partners/Orano Med)
Drug Alias Name212Pb-DARPin-MSLNLead DARPin-MSLN
ClassificationBiologics > Protein drugsRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lead > 212Pb +[4] 
Mechanisms of ActionIonising radiation emittersDelta-like protein 3 modulators
TargetsDelta-like protein 3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMolecular Partners AgOrano Med SAS
China Registration ClassN/A

Develop Information

Active CompaniesOrano Med SASMolecular Partners Ag
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A